LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Recruiting · Phase 2 · NCT07186101
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $6,299
- U.S. investigators named
- 12
- Sites paid
- 11
- Planned or actual enrollment
- 252
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4268989 (drug), Mirikizumab (drug), LY4268989 Placebo (drug)
- Dates
- Started 2025-11-10; completion 2029-03
- Results posted
- Not yet
The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 weeks of treatment and may include up to 21 visits.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $6,299 in research payments for this study in 2025 (35 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jatinder S. Pruthi, M.D. Gastroenterology · Lancaster, CA
- Isaac Bassan, M.D. Gastroenterology · Miami Beach, FL
- Kyle P. Etzkorn, MD Gastroenterology · Jacksonville, FL
- Manuel E. Rodriguez, M.D. Gastroenterology · Bradenton, FL
- Harinath Sheela, MD Gastroenterology · Orlando, FL
- Robert T. Luckett, M.D. Gastroenterology · New Albany, IN
- Michael P. Krease, D.O. Gastroenterology · Louisville, KY
- Ronald Fogel, MD Gastroenterology · Chesterfield, MI
- Jeff Bullock, M.D. Gastroenterology · San Antonio, TX
- Chad M. Gonzales, M.D. Gastroenterology · Ogden, UT
- Kara L. Foster-weiss, M,D Family Medicine · North Chesterfield, VA
- Nicholas J. Procaccini, MD Gastroenterology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $3,256
- Clinical Research PArtners LLC $619
- Gastroenterology Health PArtners PLLC $453
- Care Access Research LLC $421
- Florida Digestive Health Specialists LLP $421
- Digestive and Liver Center of Florida $388
- Southern Star Research Institute LLC $388
- Om Research LLC $96
- Washington Gastroenterology PLLC $64
- Encore Borland-Groover Clinical $64
- Henry Ford Macomb Health Center $64
- Sweet Hope Research Specialty Inc DBA Neoclinical Research $64
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.